Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3034701 in Japanese Participants With Obesity/Overweight and Healthy Volunteers
NCT07693231Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in obesity and Overweight comparing BI 3034701 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 19 weeks. Started Jul 2026; status: active, not recruiting.
02
Drugs
BI 3034701
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07693231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693231.